Stock listing
Frankfurt:4RM Catheter Precision, Inc. Aktie
German listing (Frankfurt) of Catheter Precision, Inc. · home listing NYSE American:VTAK
Follow Catheter Precision, Inc. into a list and get an email when it puts out news.

- Ticker
- Frankfurt:4RM
- Asset type
- Stock
- Sector
- Health care
- Industry
- Medical devices & supplies
- Exchange
- Frankfurt
- Currency
- EUR
What changed lately
Latest news release · Sep 17, 2026
Catheter Precision Expands LockeT Commercialization Across Latin America Following Successful Launch in Brazil
Latest news
Catheter Precision, Inc. on 6ix
- Sector
- Health care
- Industry
- Medical devices & supplies
- News releases
- 40 in the last 12 months · 66 in all · newest Sep 17, 2026 · oldest 2025
- Decks
- 11 decks · latest Mar 12, 2025
Where Catheter Precision, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NYSE American:VTAK · Home listing | NYSE American | United States | USD |
| BOATS:VTAK | BOATS | United States | USD |
| Frankfurt:4RM · This page | Frankfurt | Germany | EUR |
| gettex:4RM | gettex | Germany | EUR |
| Munich:4RM | Munich | Germany | EUR |
| Stuttgart:4RM0 | Stuttgart | Germany | EUR |
Valuation
Statements: 4 quarters to Jun 30, 2026
- Enterprise value
- No market cap
- P/E
- No market cap
- EV/sales
- No market cap
- EV/EBITDA
- No market cap
- Price/book
- No market cap
- Gross margin
- 47.7%
- Operating margin
- −635.0%
- Net margin
- −661.4%
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 0.97
Forecasts
1 strong buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 2.00 USD · Analysts' mean
- EPS, year to Dec 2024
- -8.70 · 1 analyst
- Revenue, year to Dec 2024
- 3.19M · 1 analyst
Team and board
| Officer | Role |
|---|---|
| David Jenkins | Chief Executive Officer |
| Phil Anderson | Chief Financial Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2026 | Nov 12, 2026 | |
| Q2 2026 | Aug 14, 2026 | −20.7% |
| Q1 2026 | May 18, 2026 | +7.9% |
| Q3 2025 | Nov 13, 2025 | −16.0% |
| Q2 2025 | Aug 11, 2025 | −10.5% |
| Q1 2025 | May 5, 2025 · After close | −3.6% |
| Q4 2024 | Mar 27, 2025 · After close | −7.9% |
| Q3 2024 | Nov 14, 2024 · Before open | +4.2% |
| Q2 2024 | Aug 14, 2024 · Before open | +1.9% |
| Q1 2024 | May 6, 2024 · After close | +1.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q4 2023 | Mar 29, 2024 · After close | +2.0% |
| Q3 2023 | Dec 21, 2023 · After close | +5.0% |
| Q2 2023 | Aug 14, 2023 | −1.6% |
| Q1 2023 | Jun 2, 2023 · After close | +1.9% |
| Q4 2022 | Mar 14, 2023 | −0.6% |
| Q3 2022 | Nov 16, 2022 | −9.2% |
| Q2 2022 | Aug 15, 2022 | |
| Q1 2022 | May 16, 2022 | |
| Q4 2021 | Mar 23, 2022 | |
| Q3 2021 | Nov 15, 2021 |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (March 2025) | Investor deck | 25 slides | Mar 12, 2025 |
| IPO Roadshow (June 2024) | IPO roadshow | 101 slides | Jun 17, 2024 |
| Ra Medical Systems — IPO Roadshow (January 2022) | IPO roadshow | 21 slides | Jan 28, 2022 |
| Ra Medical Systems — Investor Presentation (August 2021) | Investor deck | 19 slides | Aug 24, 2021 |
| Ra Medical Systems — Investor Presentation (March 2021) | Investor deck | 20 slides | Mar 8, 2021 |
| Ra Medical Systems — Investor Presentation (January 2021) | Investor deck | 25 slides | Jan 5, 2021 |
| Ra Medical Systems — Investor Presentation (September 2020) | Investor deck | 25 slides | Sep 14, 2020 |
| Ra Medical Systems — IPO Roadshow (July 2020) | IPO roadshow | 26 slides | Jul 27, 2020 |
| Ra Medical Systems — IPO Roadshow (May 2020) | IPO roadshow | 26 slides | May 15, 2020 |
| Ra Medical Systems — Investor Presentation (December 2019) | Investor deck | 25 slides | Dec 11, 2019 |
All 11 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Ra Medical Systems — Investor Presentation (November 2018) | Investor deck | 24 slides | Nov 13, 2018 |
Financings
| Raise | Date |
|---|---|
| Strategic investment of not specified Announced: up to US$36.5M Use of proceeds: Advance key growth initiatives, scale multiple business opportunities and expand market presence and execution capabilities | Feb 12, 2026 |
| Private placement of series B Preferred Stock and warrants Closed: US$1.5M raised · ½ warrant at US$0.5 for 66 months · Ladenburg Thalmann & Co. Inc. Dealers: Ladenburg Thalmann & Co. Inc. (lead) | May 12, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 819.0K | 420.0K | 442.0K | 14.0K | 22.0K | 4.41M | 7.20M | 6.26M | 5.87M | 5.98M |
| Cost of revenue | 63.0K | 42.0K | 30.0K | 161.0K | 1.56M | 5.48M | 8.85M | 4.21M | 4.17M | 3.14M |
| Gross profit | 756.0K | 378.0K | 412.0K | -147.0K | -1.54M | -1.08M | -1.65M | 2.05M | 1.71M | 2.84M |
| Research and development | 862.0K | 272.0K | 475.0K | 6.39M | 12.3M | 9.01M | 4.53M | 2.78M | 4.52M | 1.72M |
| Selling, general and administrative | 12.1M | 11.3M | 17.1M | 2.23M | 15.5M | 26.0M | 51.5M | 30.4M | ||
| Operating income | -12.2M | -11.2M | -78.1M | -27.0M | -29.3M | -36.1M | -57.7M | -31.2M | -17.8M | -4.20M |
| Depreciation and amortization | 2.12M | 2.11M | 2.08M | 421.0K | 1.56M | 2.37M | 1.75M | 624.0K | 218.0K | 95.0K |
| EBITDA | -10.1M | -9.13M | -76.0M | -26.5M | -27.7M | -33.7M | -56.0M | -30.5M | -17.5M | -4.10M |
| Interest expense | 281.0K | 91.0K | 0 | 3.08M | 10.0K | 108.0K | 250.0K | 14.0K | 4.00K | 3.00K |
| Income before tax | -19.5M | -13.5M | -70.6M | -26.9M | -27.3M | -36.0M | -56.9M | -30.8M | -17.8M | -4.20M |
| Income tax | -1.81M | 3.14M | 60.6M | 3.00K | 4.00K | 7.00K | 15.0K | 10.0K | 1.00K | 1.00K |
| Net income | -17.2M | -16.6M | -70.6M | -26.9M | -25.1M | -36.0M | -57.0M | -30.8M | -17.8M | -4.20M |
| Earnings per share, basic | -15.90 | -96.89 | -2,440.16 | -4,936.60 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 88.0K | 2.87M | 3.56M | 15.9M | 15.0M | 23.9M | 14.6M | 64.3M | 8.24M | 3.92M |
| Short-term investments | 0 | 16.0M | ||||||||
| Receivables | 155.0K | 70.0K | 137.0K | 75.6K | 21.0K | 24.0K | 786.0K | 1.32M | 517.0K | 393.0K |
| Inventory | 86.0K | 33.0K | 44.0K | 52.4K | 986.0K | 877.0K | 2.78M | 2.10M | 1.20M | 870.0K |
| Current assets | 390.0K | 3.29M | 4.16M | 16.8M | 17.1M | 27.6M | 36.0M | 69.2M | 10.0M | 5.31M |
| Property, plant and equipment | 3.92M | 5.01M | ||||||||
| Total assets | 15.9M | 27.8M | 30.7M | 16.8M | 21.0M | 33.4M | 44.1M | 74.0M | 11.3M | 5.84M |
| Accounts payable | 1.49M | 230.0K | 464.0K | 92.0K | 988.0K | 471.0K | 1.53M | 1.13M | 426.0K | 473.0K |
| Current liabilities | 3.91M | 2.08M | 2.47M | 7.58M | 5.39M | 7.76M | 6.81M | 5.95M | 2.63M | 2.71M |
| Long-term debt | 3.08M | 1.50M | 1.58M | 265.0K | ||||||
| Total debt | 3.85M | 1.79M | 372.0K | 124.2K | 2.26M | 4.88M | 3.50M | 850.0K | 63.0K | 107.0K |
| Total liabilities | 9.21M | 16.0M | 9.54M | 7.58M | 7.37M | 12.3M | 10.9M | 7.33M | 18.9M | 6.22M |
| Shareholders' equity | 7.05M | 11.8M | 21.2M | 9.26M | 13.7M | 21.1M | 33.1M | 66.7M | -7.62M | -380.0K |
| Shares outstanding | 1.08M | 171.8K | 28.9K | 5.44K | 532 | 179 | 55 | 53 | 53 | 53 |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.30M | -9.27M | -20.6M | -22.6M | -27.6M | -28.3M | -33.2M | -18.5M | -5.52M | -1.89M |
| Capital spending | -17.0K | -67.0K | -76.0K | -17.0K | -265.0K | -67.0K | -268.0K | -582.0K | -547.0K | -210.0K |
| Free cash flow | -8.31M | -9.34M | -20.7M | -22.6M | -27.9M | -28.4M | -33.4M | -19.1M | -6.07M | -2.10M |
| Cash from investing | 167.0K | -67.0K | -61.0K | 21.0K | 3.80M | 15.9M | -16.0M | -582.0K | -547.0K | -210.0K |
| Cash from financing | 5.34M | 8.65M | 8.39M | 23.4M | 15.0M | 21.7M | -526.0K | 75.2M | 10.4M | 5.37M |
| Dividends paid | -5.16M | -907.2K | ||||||||
| Change in cash | -2.79M | -692.0K | -12.3M | 814.0K | -8.86M | 9.32M | -49.7M | 56.1M | 4.32M | 3.28M |
Cap table
Built by 6ix from Catheter Precision, Inc.’s releases · as of Feb 12, 2026
- Common shares
- 1,897,204
- Fully diluted
- 1,897,954
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 1,897,204 | |
| Warrants | 750 | May 12, 2025 |
Warrants and options
| Lot |
|---|
| Warrants · US$0.50 · expire about Nov 2030 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,897,204 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| David Jenkins Other companies: Intelligent Bio Solutions Inc. (Director · Oct 4, 2022 – Oct 4, 2022 · Past) | Chief Executive Officer · Since at least Jan 16, 2024 |
| Martin J Colombatto Other companies: PLX Technology Inc (Director · Dec 19, 2013 – Aug 12, 2014 · Past) | Director · Since at least Jan 8, 2024 |
| John P Francis | Director · Jan 2, 2024 – Jan 8, 2024 · Past |
| Marie-Claude Jacques | Chief Commercial Officer · May 1, 2024 – Jan 29, 2025 · Past |
| Phil Anderson | Chief Financial Officer · Since at least Apr 23, 2025 |
Log in to ask 6ix AI your own questions about Catheter Precision, Inc.